Abstract
Thrombocytopenia is frequently encountered in HIV-infected patients, and the predominant cause is primary HIV-associated thrombocytopenia (PHAT). Standard treatment regimens include optimization of antiretroviral therapy, intravenous immunoglobulin, anti-D, and corticosteroids. Retreatment due to the inability to sustain remission or inferior responses is common, and investigation into the safety and efficacy of alternative therapies is warranted. We describe novel and effective treatment of PHAT with the peptide thrombopoietin receptor agonist romiplostim in a patient with a minimal response to conventional therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 22-23 |
| Number of pages | 2 |
| Journal | Journal of the International Association of Providers of AIDS Care |
| Volume | 13 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2014 |
Fingerprint
Keywords
- HIV
- peptide thrombopoietin receptor agonist
- primary HIV-associated thrombocytopenia
- romiplostim
- thrombocytopenia
ASJC Scopus subject areas
- Immunology
- Dermatology
- Infectious Diseases
Cite this
Use of peptide thrombopoietin receptor agonist romiplostim (Nplate) in a case of primary HIV-associated thrombocytopenia. / Aslam, M. Imran; Cardile, Anthony P.; Crawford, George E.
In: Journal of the International Association of Providers of AIDS Care, Vol. 13, No. 1, 01.2014, p. 22-23.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Use of peptide thrombopoietin receptor agonist romiplostim (Nplate) in a case of primary HIV-associated thrombocytopenia
AU - Aslam, M. Imran
AU - Cardile, Anthony P.
AU - Crawford, George E
PY - 2014/1
Y1 - 2014/1
N2 - Thrombocytopenia is frequently encountered in HIV-infected patients, and the predominant cause is primary HIV-associated thrombocytopenia (PHAT). Standard treatment regimens include optimization of antiretroviral therapy, intravenous immunoglobulin, anti-D, and corticosteroids. Retreatment due to the inability to sustain remission or inferior responses is common, and investigation into the safety and efficacy of alternative therapies is warranted. We describe novel and effective treatment of PHAT with the peptide thrombopoietin receptor agonist romiplostim in a patient with a minimal response to conventional therapy.
AB - Thrombocytopenia is frequently encountered in HIV-infected patients, and the predominant cause is primary HIV-associated thrombocytopenia (PHAT). Standard treatment regimens include optimization of antiretroviral therapy, intravenous immunoglobulin, anti-D, and corticosteroids. Retreatment due to the inability to sustain remission or inferior responses is common, and investigation into the safety and efficacy of alternative therapies is warranted. We describe novel and effective treatment of PHAT with the peptide thrombopoietin receptor agonist romiplostim in a patient with a minimal response to conventional therapy.
KW - HIV
KW - peptide thrombopoietin receptor agonist
KW - primary HIV-associated thrombocytopenia
KW - romiplostim
KW - thrombocytopenia
UR - http://www.scopus.com/inward/record.url?scp=84893081217&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893081217&partnerID=8YFLogxK
U2 - 10.1177/2325957413502539
DO - 10.1177/2325957413502539
M3 - Article
C2 - 24036490
AN - SCOPUS:84893081217
VL - 13
SP - 22
EP - 23
JO - Journal of the International Association of Providers of AIDS Care
JF - Journal of the International Association of Providers of AIDS Care
SN - 2325-9574
IS - 1
ER -